免疫实践咨询委员会关于5-11岁儿童使用辉瑞-BioNTech COVID-19疫苗的临时推荐——美国,2021年11月
2021年10月29日,美国FDA发布紧急使用授权(EUA)修订,批准辉瑞-BioNTech COVID-19疫苗新配方用于5-11岁儿童,接种2剂(10 μg,0.2 mL),间隔3周。2021年11月2日,免疫实践咨询委员会(ACIP)基于证据到推荐(EtR)框架和GRADE方法,发布该疫苗用于5-11岁儿童预防COVID-19的临时推荐。该疫苗在5-11岁儿童中对COVID-19具有高效力(>90%),ACIP判定接种获益大于风险。接种对保护儿童和减少SARS-CoV-2社区传播具有重要意义。
要点
- ACIP临时推荐5-11岁儿童使用辉瑞-BioNTech COVID-19疫苗,接种2剂(10 μg,0.2 mL),间隔3周。
- 该疫苗在5-11岁儿童中对COVID-19的效力>90%,ACIP判定获益大于风险。
- 2021年10月29日FDA发布EUA修订,批准该疫苗新配方用于5-11岁儿童。
- ≥12岁人群推荐接种2剂(30 μg,0.3 mL),间隔3周;截至2021年11月2日美国已接种约2.48亿剂。
- ACIP推荐为临时性,将随新信息更新。
适用人群与场景
- 5-11岁儿童,用于预防COVID-19。
- ≥12岁人群推荐接种2剂(30 μg,0.3 mL),间隔3周;12-15岁青少年在EUA下推荐接种。
处置流程与药物剂量
- 5-11岁儿童:接种辉瑞-BioNTech COVID-19疫苗2剂(10 μg,0.2 mL),间隔3周。
- ≥12岁人群:接种2剂(30 μg,0.3 mL),间隔3周。
研究设计与关键结果
- ACIP使用证据到推荐(EtR)框架并纳入GRADE方法制定推荐。
- 辉瑞-BioNTech COVID-19疫苗在5-11岁儿童中对COVID-19具有高效力(>90%),ACIP判定接种获益大于风险。
- 截至2021年11月2日,美国≥12岁人群已接种约2.48亿剂辉瑞-BioNTech COVID-19疫苗。
证据类型、等级与局限
- 证据类型:免疫实践咨询委员会(ACIP)临时推荐,基于EtR框架和GRADE方法。
- 该推荐为临时性,将随新信息更新。
对床旁实践的改变
- 5-11岁儿童可按ACIP临时推荐接种辉瑞-BioNTech COVID-19疫苗2剂(10 μg,0.2 mL),间隔3周。
- 接种对保护儿童和减少SARS-CoV-2社区传播具有重要意义。
指南或共识出处
- 免疫实践咨询委员会(ACIP)临时推荐,2021年11月2日发布。
- 美国食品药品监督管理局(FDA)紧急使用授权(EUA)修订,2021年10月29日发布。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Application (BLA) for use of the Pfizer-BioNTech COVID-19 vaccine, marketed as Comirnaty (Pfizer, Inc.), in persons aged ≥16 years (1). The Pfizer-BioNTech COVID-19 vaccine is also recommended for adolescents aged 12-15 years under an Emergency Use Authorization (EUA) (1). All persons aged ≥12 years are recommended to receive 2 doses (30 μg, 0.3 mL each), administered 3 weeks apart (2,3). As of November 2, 2021, approximately 248 million doses of the Pfizer-BioNTech COVID-19 vaccine had been administered to persons aged ≥12 years in the United States.* On October 29, 2021, FDA issued an EUA amendment for a new formulation of Pfizer-BioNTech COVID-19 vaccine for use in children aged 5-11 years, administered as 2 doses (10 μg, 0.2 mL each), 3 weeks apart (Table) (1). On November 2, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation† for use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years for the prevention of COVID-19. To guide its deliberations regarding recommendations for the vaccine, ACIP used the Evidence to Recommendation (EtR) Framework§ and incorporated a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.¶ The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years under an EUA is interim and will be updated as additional information becomes available. The Pfizer-BioNTech COVID-19 vaccine has high efficacy (>90%) against COVID-19 in children aged 5-11 years, and ACIP determined benefits outweigh risks for vaccination. Vaccination is important to protect children against COVID-19 and reduce community transmission of SARS-CoV-2.
参考来源
- Woodworth KR, Moulia D, Collins JP, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34758012. doi:10.15585/mmwr.mm7045e1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。